- Gilead Sciences (NASDAQ:GILD): Q3 Non-GAAP EPS of $2.11 beats by $0.22; GAAP EPS of $0.29 misses by $0.96.
- Revenue of $6.56B (+17.1% Y/Y) beats by $260M.
- R&D expenses of $1.16B vs. $1.19B consensus.
- FY20 EPS of $6.25-$6.60 from prior guidance of $6.25-$7.65 vs. $6.87 consensus.
- Press Release
https://seekingalpha.com/news/3627604-gilead-sciences-eps-beats-0_22-beats-on-revenue
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.